SOX11+ Large B-Cell Neoplasms : Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Copyright © 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved..
Large or blastoid B-cell neoplasms that are SOX11+ are a diagnostic dilemma and raise a differential diagnosis of cyclin D1-negative blastoid/pleomorphic mantle cell lymphoma (MCL) versus diffuse large B-cell lymphoma (DLBCL) or blastoid high-grade B-cell lymphoma (HGBL) with aberrant SOX11 expression. Here we report a study cohort of 13 SOX11+ large/blastoid B-cell neoplasms. Fluorescence in situ hybridization analysis was negative for CCND1 rearrangement in all 13 cases; 1 of 8 (12.5%) cases tested showed CCND2 rearrangement and 2 (25%) cases had extracopies of CCND2. Gene expression profiling showed that the study group had a gene expression signature similar to cyclin D1+ blastoid/pleomorphic MCL but different from DLBCL. Principal component analysis revealed that the cohort cases overlapped with cyclin D1+ blastoid/pleomorphic MCL but had minimal overlap with DLBCL. All patients in the cohort had clinicopathologic features similar to those reported for patients with cyclin D1+ MCL. We also performed a survey of SOX11 expression in a group of 85 cases of DLBCL and 24 cases of blastoid HGBL. SOX11 expression showed a 100% specificity and positive predictive value for the diagnosis of MCL. Overall, the results support the conclusion that large or blastoid B-cell neoplasms that are positive for SOX11 are best classified as cyclin D1-negative blastoid/pleomorphic MCL, and not as DLBCL or blastoid HGBL. We also conclude that SOX11 is a specific marker for the diagnosis of MCL, including cyclin D1-negative blastoid/pleomorphic MCL cases and should be performed routinely on blastoid/large B-cell neoplasms to help identify potential cases of cyclin D1-negative blastoid/pleomorphic MCL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 37(2024), 2 vom: 01. Feb., Seite 100405 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Shaoying [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.modpat.2023.100405 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365955876 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365955876 | ||
| 003 | DE-627 | ||
| 005 | 20240229154731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.modpat.2023.100405 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM365955876 | ||
| 035 | |a (NLM)38104893 | ||
| 035 | |a (PII)S0893-3952(23)00310-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Shaoying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SOX11+ Large B-Cell Neoplasms |b Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Large or blastoid B-cell neoplasms that are SOX11+ are a diagnostic dilemma and raise a differential diagnosis of cyclin D1-negative blastoid/pleomorphic mantle cell lymphoma (MCL) versus diffuse large B-cell lymphoma (DLBCL) or blastoid high-grade B-cell lymphoma (HGBL) with aberrant SOX11 expression. Here we report a study cohort of 13 SOX11+ large/blastoid B-cell neoplasms. Fluorescence in situ hybridization analysis was negative for CCND1 rearrangement in all 13 cases; 1 of 8 (12.5%) cases tested showed CCND2 rearrangement and 2 (25%) cases had extracopies of CCND2. Gene expression profiling showed that the study group had a gene expression signature similar to cyclin D1+ blastoid/pleomorphic MCL but different from DLBCL. Principal component analysis revealed that the cohort cases overlapped with cyclin D1+ blastoid/pleomorphic MCL but had minimal overlap with DLBCL. All patients in the cohort had clinicopathologic features similar to those reported for patients with cyclin D1+ MCL. We also performed a survey of SOX11 expression in a group of 85 cases of DLBCL and 24 cases of blastoid HGBL. SOX11 expression showed a 100% specificity and positive predictive value for the diagnosis of MCL. Overall, the results support the conclusion that large or blastoid B-cell neoplasms that are positive for SOX11 are best classified as cyclin D1-negative blastoid/pleomorphic MCL, and not as DLBCL or blastoid HGBL. We also conclude that SOX11 is a specific marker for the diagnosis of MCL, including cyclin D1-negative blastoid/pleomorphic MCL cases and should be performed routinely on blastoid/large B-cell neoplasms to help identify potential cases of cyclin D1-negative blastoid/pleomorphic MCL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CCND1 | |
| 650 | 4 | |a CCND2 | |
| 650 | 4 | |a Cyclin D1-negative mantle cell lymphoma | |
| 650 | 4 | |a SOX11 | |
| 650 | 4 | |a blastoid high-grade B-cell lymphoma | |
| 650 | 4 | |a blastoid/pleomorphic | |
| 650 | 4 | |a diffuse large B-cell lymphoma | |
| 650 | 7 | |a Cyclin D1 |2 NLM | |
| 650 | 7 | |a 136601-57-5 |2 NLM | |
| 650 | 7 | |a SOX11 protein, human |2 NLM | |
| 650 | 7 | |a SOXC Transcription Factors |2 NLM | |
| 700 | 1 | |a Tang, Guilin |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Preetesh |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Roberto N |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, C Cameron |e verfasserin |4 aut | |
| 700 | 1 | |a You, M James |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Michael L |e verfasserin |4 aut | |
| 700 | 1 | |a Medeiros, L Jeffrey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc |d 1992 |g 37(2024), 2 vom: 01. Feb., Seite 100405 |w (DE-627)NLM012660051 |x 1530-0285 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:100405 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.modpat.2023.100405 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2024 |e 2 |b 01 |c 02 |h 100405 | ||